

- Pericarditis (*Continued*)  
in systemic lupus erythematosus, 780-781  
traumatic, 146
- Pericardium, 136  
anatomy and physiology of, 16  
lipomas of, 145  
trauma to, 146-147, 146t
- Pericholangitis, inflammatory bowel disease with, 419-420
- Perimenopausal symptoms, 707-708, 707t
- Perimenopause, to menopause, 707
- Periodic limb movement disorder (PLMD), 973
- Periodic paralyses, 1095
- Periodontal infections, 869
- Perioperative Ischemic Evaluation (POISE) trial, 275
- Peripartum cardiomyopathy (PCM), 157
- Peripheral arterial disease, 159-161, 159t, 160f  
diagnosis of, 159, 159t  
future prospectus for, 179
- Peripheral blood smear, 508-509
- Peripheral blood stem cells (PBSCs), in stem cell transplantation, 481-482
- Peripheral edema, in heart failure, 59
- Peripheral joint disease, spondyloarthritis and, 776
- Peripheral nerve, disorders of, 1080-1084, 1082t
- Peripheral neuropathies  
classification and causes of, 1080t  
diabetic, 1085  
laboratory studies of, 1083t  
mononeuropathies, common examples of, 1081t, 1084  
polyneuropathies, 670-671  
acquired, specific, 1084-1085  
hereditary, 1085-1086  
symptomatic treatment for, 1084t
- Peripheral vein, parenteral nutrition administration in, 687-688
- Peritoneal dialysis, 368, 368.e1f
- Peritonitis  
during peritoneal dialysis, 898  
primary, 897  
secondary, 897-898  
spontaneous bacterial, 462  
tuberculous, 898
- Peritonsillar abscess, pharyngitis and, 869
- Peritubular capillaries, 282
- Pernicious anemia, 506
- Peroneal neuropathy, 1084
- Persistent depressive disorder, 985
- Persistent diarrhea, 899
- Persistent vegetative states (PVS), 969
- Personality, definition of, 989
- Personality disorders, 987t, 989
- Pertuzumab, 590t
- PET. *see* Positron emission tomography (PET)
- Petit mal, 1055, 1055f
- Petit mal epilepsy, 1056
- pH, esophageal, monitoring of, 397
- Phagocytic cells, 517, 826-827
- Phagocytosis  
of *Mycobacterium tuberculosis*, 829  
by neutrophils, 515, 825
- Pharmacogenetics, 13
- Pharmacogenomics, 11
- Pharmacologic stress testing, for coronary artery disease, 93
- Pharyngitis, 868-869, 869t
- Phencyclidine (PCP), 1136
- Phenobarbital, 1060t
- Phenothiazines, for migraine, 995-996
- Phenoxybenzamine, for pheochromocytoma, unresectable, 172
- Phentermine, for obesity, 679-680
- Phentolamine, penile injection of, 719
- Phenytoin, 1060t  
in traumatic brain injury, 1047
- Pheochromocytoma, 170t, 171-172, 650-651  
hypercalcemia with, 743
- Philadelphia chromosome, 489, 588-589  
detection of, 493
- Phlebitis, suppurative, 882-883
- Phobia, 987-988
- Phosphate  
in acute kidney injury, 361.e1t  
chronic kidney disease and, 366  
excessive renal losses of, 748  
excessive skeletal mineralization and, 748  
homeostasis of, 737-739, 738f  
inadequate intake of, 747-748  
intestinal absorption of, 738  
intracellular-extracellular fluxes of, 738  
measurements of, 737  
physiologic roles of, 737  
renal handling of, 738-739  
shift into extracellular fluid, 748  
skeletal fluxes, 738  
therapeutic preparations of, 737t
- Phosphatonins, 739
- Phosphenes, 1006
- Phosphodiesterase type 5 inhibitors  
for benign prostatic hyperplasia, 722  
for erectile dysfunction, 718  
vacuum constriction devices with, 719  
for pulmonary arterial hypertension, 164
- Photopsias, 1006
- Physical activity, cancer risk and, 580
- Physical maps, 8
- Physical therapy  
for rheumatoid arthritis, 773  
for spondyloarthritis, 778  
for systemic sclerosis, 792
- Physiologic anisocoria, 1002-1003
- Pickwickian syndrome, 245-246
- Pigment nephropathy, in intrinsic acute kidney injury, 359
- "Pink puffer", 211
- Pinworm, 955
- Pioglitazone, for nonalcoholic fatty liver disease and, 455
- Piperazines, 1137
- Pitting edema, 26
- Pituitary gland  
anatomy and physiology of, 624, 624f  
hormones, 624, 625t. *see also specific hormones*  
posterior, 624  
screening tests for disorders of, 626t
- Pituitary tumors, 624-625, 625t-626t  
ACTH-secreting, 626t, 630-631  
gonadotropin-secreting, 626t, 631  
growth hormone-secreting. *see* Acromegaly
- Pituitary tumors (*Continued*)  
prolactinoma, 626  
TSH-secreting, 626t, 629
- Plague, 844
- Plain film radiography, abdominal, for chronic pancreatitis, 433-434
- Plain old balloon angioplasty (POBA), in angina pectoris, 96
- Plain radiographs, abdominal, 392, 393f
- Plasma  
fresh frozen, 561, 561.e1f  
tonicity of, 299
- Plasma cell disorders, 529-533  
rare, 532-533
- Plasma cell dyscrasias, glomerular diseases from, 323-324
- Plasma cells, 521
- Plasma exchange  
for hemolytic uremic syndrome, 570  
for thrombotic thrombocytopenic purpura, 570
- Plasma lipoprotein (a), elevated, 695
- Plasmacytoma, 529
- Plasmapheresis  
for Guillain-Barré syndrome, 1085  
for myasthenia gravis, 1098  
for vasculitides, ANCA-associated, 796
- Plasmin, 542, 564
- Plasminogen activator inhibitor-1 (PAI-1), 541, 541f, 564, 571  
in obesity, 677
- Plasminogen activator receptor, soluble urokinase-type, 316
- Plasmodium falciparum*, 952
- Plasmodium* species, 954t
- Platelet count, 535  
elevated, 491  
reticulated, 548
- Platelet dysfunction  
acquired causes of, 554-556  
congenital causes of, 556
- Platelet Function Analyzer-100 (PFA-100), 535, 545
- Platelet refractoriness, 557-558
- Platelet transfusion, 556-558, 557.e1f  
in acute renal failure, 556  
for bleeding caused by drugs, 555  
in congenital platelet dysfunction, 556  
contraindicated in thrombotic thrombocytopenic purpura, 570  
failure of, 557-558  
for immune thrombocytopenic purpura, 551  
platelet refractoriness and, 557-558  
standard, 556-557
- Platelets, 480  
activation of, 538-539  
bleeding time and, 535  
circulating lifetime, 535  
glycoprotein defects of, 556  
granule or secretory defects of, 556  
hemostasis, 535  
physiology, 535-539  
procoagulant properties of, 538t  
thrombosis associated with  
atherothrombosis, 565, 565t  
venous, 568-569